Successful treatment of patients with acute myeloid leukemia and Myelodysplastic Syndrome by decitabine

Basit Öğe Kaydı
dc.authorscopusid56495083200
dc.authorscopusid57208321258
dc.authorscopusid56699810200
dc.authorscopusid57440306700
dc.authorscopusid13003715700
dc.authorscopusid6701575271
dc.contributor.authorBulbul, Hale
dc.contributor.authorDavulcu, Eren A.
dc.contributor.authorAtilla, Fatos D.
dc.contributor.authorUlusoy, Yusuf
dc.contributor.authorSoyer, Nur
dc.contributor.authorSaydam, Guray
dc.date.accessioned2023-01-12T20:19:29Z
dc.date.available2023-01-12T20:19:29Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractObjectives: The goal of this study was to identify the safety and efficacy of decitabine. Design: Retrospective study Setting: Department of Hematology, Ege University Faculty of Medicine Subjects: Data of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who were treated with decitabine were evaluated retrospectively. Intervention(s): Decitabine was administered 20 mg/m(2) by intravenous infusion daily for five consecutive days every four weeks. The primary end point was overall response rate (ORR). Survival, overall improvement rate (OIR), hematologic improvement (HI) and drug toxicity were analyzed. Main outcome measure(s): Overall survival (OS), progression-free survival (PFS), ORR and hematologic adverse event for both AML and MDS, OIR including HI for MDS. Results: Twenty-five MDS and thirteen AML patients were enrolled. In MDS group, median OS and PFS were 21 months and 14 months, respectively. The ORR was 48% and OIR was 60%, which included 12% HI. Seventy-two of the patients experienced stable disease or better. For AML, ORR was 46.2%, and median OS and PFS data were not reached as 76% (n=10) of patients are still alive, and 38% (n=5) of patients are still receiving treatment. At one year, OS and PFS were 61.4% and 77.8%, respectively. Conclusion: Decitabine is effective and safe with acceptable toxicity in intermediate and high-risk MDS patients and elderly patients with AML.en_US
dc.identifier.endpage391en_US
dc.identifier.issn1607-8047
dc.identifier.issn0023-5776
dc.identifier.issn1607-8047en_US
dc.identifier.issn0023-5776en_US
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85140357206en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage385en_US
dc.identifier.urihttps://hdl.handle.net/11454/79139
dc.identifier.volume54en_US
dc.identifier.wosWOS:000891831700011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKuwait Medical Assocen_US
dc.relation.ispartofKuwait Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectadministration and dosageen_US
dc.subjectadverse effectsen_US
dc.subjectsurvival analysisen_US
dc.subjectPhase-Iiien_US
dc.subjectSupportive Careen_US
dc.subjectDna Methylationen_US
dc.subjectOlder Patientsen_US
dc.subjectMulticenteren_US
dc.subjectClassificationen_US
dc.subjectOrganizationen_US
dc.titleSuccessful treatment of patients with acute myeloid leukemia and Myelodysplastic Syndrome by decitabineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu